| Title | Author(s) | Year | View Count |
 | Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? | Wong, H; Wong, KP; Yau, T; Tang, V; Leung, R; Chiu, J; Lang, BHH | 2012 | 78 |
 | Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer | Wong, H; Lau, S; Leung, R; Chiu, J; Cheung, P; Wong, TT; Liang, R; Epstein, RJ; Yau, T | 2012 | 63 |
| The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits | Chiu, J; Tang, YF; Yao, TJ; Wong, A; Wong, H; Leung, R; Chan, P; Cheung, TT; Chan, AC; Pang, R; Fan, ST; Poon, R; Yau, T | 2012 | 81 |
 | Colon cancer in a patient with underlying aplastic anemia: A clinical challenge | Wong, H; Chan, P; Yau, TCC | 2012 | 48 |
| Ki67 proliferation index in invasive lobular carcinoma of the breast: clinicopathologic correlation and prognostic significance | Wong, H; Lau, S; Cheung, P; Leung, R; Chiu, J; Wong, TT; Liang, R; Epstein, RJ; Yau, TCC | 2012 | 179 |
| Comparison of clinicopathologic features of invasive lobular carcinoma of the breast with or without associated lobular carcinoma in-situ | Yau, TCC; Wong, H; Lau, S; Leung, R; Chiu, J; Wong, TT; Liang, R; Epstein, RJ; Cheung, P | 2012 | 57 |
| Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease | Yau, T; Wong, H; Chan, P; Yao, TJ; Pang, R; Cheung, TT; Fan, ST; Poon, RT | 2012 | 97 |
| Targeted therapy in the management of advanced gastric cancer: Are we making progress in the Era of personalized medicine? | Wong, H; Yau, T | 2012 | 68 |
| Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy | Leung, R; Lang, B; Wong, H; Chiu, J; Wan, KY; Shek, T; Woo, YC; Lo, CY; Yau, T | 2012 | 50 |
| The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (hcc) | Wong, H; Tang, YF; Yao, TJ; Chiu, J; Leung, R; Chan, P; Cheung, TT; Chan, AC; Pang, RW; Poon, R; Fan, ST; Yau, T | 2011 | 133 |
| Metronomic chemotherapy for advanced cutaneous angiosarcoma | Wong, H; Yau, T | 2011 | 118 |
| The outcomes of elderly patients with advanced hepatocellular carcinoma treated with single agent Sorafenib (Abstract) | Chan, P; Wong, H; Yao, TJ; Tang, VWK; Wong, H; Fan, ST; Poon, RTP; Yau, TCC | 2011 | 117 |
| Presence of an in-situ component predicts reduced tumor aggressiveness in luminal subtype of invasive breast cancer | Wong, H; Leung, RCY; Lau, S; Chiu, J; Cheung, P; Wong, T; Liang, R; Epstein, R; Yau, T | 2011 | 149 |
| Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: a prospective, open-label, phase II study | Yau, T; Leung, RC; Wong, H; Chiu, J; Chan, P; Pang, R; Fan, ST; Poon, RTP | 2011 | 163 |
| The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis | Chiu, J; Tang, YF; Yao, TJ; Wong, A; Wong, H; Leung, R; Chan, P; Cheung, TT; Poon, RTP; Fan, ST; Yau, CC | 2011 | 192 |
| Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocellular carcinoma after sorafenib failure: a prospective, open-label, phase II study (Abstract) | Yau, TCC; Leung, RCY; Wong, H; Chiu, J; Chan, P; Pang, RWC; Fan, ST; Poon, RTP | 2011 | 185 |
| The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib | Yau, T; Yao, TJ; Chan, P; Wong, H; Pang, R; Fan, ST; Poon, RTP | 2011 | 208 |
| Integrating molecular mechanisms and clinical evidence in the management of Trastuzumab resistant or refractory Her-2 + metastatic breast cancer | Wong, H; Leung, R; Kwong, A; Chiu, J; Liang, R; Swanton, C; Yau, T | 2011 | 82 |
| Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer | Wong, H; Lau, S; Yau, T; Cheung, P; Epstein, RJ | 2010 | 133 |
| PPI-delayed diagnosis of gastrinoma: Oncologic victim of pharmacologic success | Wong, H; Yau, T; Chan, P; Ng, IOL; Chan, G; Hui, P; Law, WL; Lo, CM; Hedley, AJ; Epstein, RJ | 2010 | 388 |
|
